KaydedilenlerDerginizi ekleyin

Dergiler / Marmara Medical Journal / 2026 / Volume: 24 Issue: 1

Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi

-

Özlem Tarçın
Sayfa
—
Yayın Tarihi
2015-04-21
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Tüm çalışmalar anjiografik olarak koroner arter hastalığı(KAH) kanıtlanmış olan hastalarda PON1 düzeyinin düştüğünü göstermektedir.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Anti-oksidan bir enzim olan paraoksonaz-1(PON1) enzim düzeyi ve aktivitesi, koroner arter hastalığı ile ilişkili olan hipertansiyon, diyabet, hiperlipidemi ve sigara kullanımı ile azalmaktadır.
📊
Temel Bulgular & Veri:Tüm çalışmalar anjiografik olarak koroner arter hastalığı(KAH) kanıtlanmış olan hastalarda PON1 düzeyinin düştüğünü göstermektedir.
💡
Sonuç & Katkı:Anahtar Kelimeler: Paraoksonaz-1, Koroner kalp hastalıkları, PON1 polimorfizm
🔬Tür:Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Anti-oksidan bir enzim olan paraoksonaz-1(PON1) enzim düzeyi ve aktivitesi, koroner arter hastalığı ile ilişkili olan hipertansiyon, diyabet, hiperlipidemi ve sigara kullanımı ile azalmaktadır. Tüm çalışmalar anjiografik olarak koroner arter hastalığı(KAH) kanıtlanmış olan hastalarda PON1 düzeyinin düştüğünü göstermektedir. Ancak polimorfizm açısından net olarak tek bir polimorfizm ile ilişkisi gösterilememiştir. Bu bilgilerin ışığında PON1 enzim düzeyi, KAH gelişimi açısından belirleyici bir marker olabilir. Ancak bunun klinik olarak kanıtlanması için prospektif ve kontrollü çalışmalara ihtiyaç vardır. Anahtar Kelimeler: Paraoksonaz-1, Koroner kalp hastalıkları, PON1 polimorfizm

Abstract

-

🔖

Bu Makaleye Atıf Yap

Tarçın, Ö. (2015). Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi. Marmara Medical Journal, Volume: 24 Issue: 1. https://ajindex.com/articles/1286987

Kaynakça (246)

  1. Primo-Parmo SL, Sorenson RC, Teiber J, La Du
  2. BN. The human serum paraoxonase/arylesterase
  3. gene (PON1) is one member of a multigene family.
  4. Genomics 1996;33:498-507. doi:
  5. geno.1996.0225
  6. Mackness MI, Hallam SD, Peard T, Warner S,
  7. Walker CH. The separation of sheep and human
  8. serum “A”-esterase activity into the lipoprotein
  9. fraction by ultracentrifugation. Comp Biochem
  10. Physiol B 1985;82:675-677.
  11. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human
  12. paraoxonase-3 is an HDL-associated enzyme with
  13. biological activity similar to paraoxonase-1 protein
  14. but is not regulated by oxidized lipids. Arterioscler
  15. Thromb Vasc Biol 2001;21:542-547.
  16. Mochizuki H, Scherer SW, Xi T,et al. Human PON2
  17. gene at 7q21.3:cloning, multiple mRNA forms, and
  18. missense polymorphisms in the coding sequence.
  19. Gene 1998;213:149-157. doi: 10.1016/S0378-
  20. 00193-0
  21. Costa LG, Vitalone A, Cole TB, et al. Modulation of
  22. paraoxonase (PON1) activity. Biochem Pharmacol;69: 541-550. doi: 10.1016/j.bcp.22004.08.027
  23. Mueller RF, Hornung S, Furlong CE, Anderson J,
  24. Giblett ER, Motulsky AG. Plasma paraoxonase
  25. polymorphism: a new enzyme assay, population,
  26. family, biochemical and linkage studies. Am J Hum
  27. Genet 1983;35:393-408.
  28. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter
  29. RJ, Shih DM, et al. Expression of human
  30. paraoxonase (PON1) during development.
  31. Pharmacogenetics 2003;13:1-8. do.:
  32. 00008571-200306000-00007
  33. Augustinsson KB, Barr M. Age variation in plasma
  34. arylesterase activity in children. Clin Chim Acta;8:568-573. doi: 10.1016/0009-8981(63)90106-
  35. Ecobichon DJ, Stephens DS. Perinatal
  36. development of human blood esterases. Clin
  37. Pharmacol Ther 1973;14:41-47.
  38. de Roos NM, Schouten EG, Scheek LM, van Tol A,
  39. Katan MB. Replacement of dietary saturated fat
  40. with trans fat reduces serum paraoxonase activity in
  41. healthy men and women. Metabolism;51:1534-1537. doi: 10.1053/meta.2002.36305
  42. Wallace AJ, Sutherland WHF, Mann JI, Williams
  43. SM. The effect of meals rich in thermally stressed
  44. olive and safflower oils on post-prandial serum
  45. paraoxonase activity in patients with diabetes. Eur J
  46. Clin Nutr 2001;55:951-958.
  47. Deakin SP, James RW. Genetic and enviromental
  48. factors modulating serum concentrations and
  49. activities of the antioxidant enzyme paraoxonase-1.
  50. Clinical Science 2004;107: 435-447. doi:
  51. CS20040187
  52. Mackness MI, Arrol S, Durrington PN. Paraoxonase
  53. prevents accumulation of lipoperoxides in lowdensity
  54. lipoprotein. FEBS Lett. 1991;286(1-2):152-
  55. doi: 10.1016//0014-5793(91)80962-3
  56. Gordon T, Castelli WP, Hjortland MC, Kannel WB,
  57. Dawber TR. High density lipoprotein as a protective
  58. factor against coronary heart disease. The
  59. Framingham Study. Am J Med 1977;62:707-714.
  60. doi: 10.1016/00029343(77)90874-9
  61. Kaysen GA. Potential restoration of HDL function
  62. with apolipoprotein A-I mimetic peptide in end-stage
  63. renal disease. Kidney Int 2009;76(4):359-61. doi:
  64. ki.2009.205
  65. Mackness B, Hine D, Liu Y, et al. Paraoxonase-1
  66. inhibits oxidized LDL-induced MCP-1 production by
  67. endothelial cells. Biochem Biophys Res Commun;318:680-683. doi: 10.1016/j.bbrc.2004.04.056
  68. Ferretti G, Bacchetti T, Marchionni C,et al. Effect of
  69. glycation of high density lipoproteins on their
  70. physiochemical properties and on paraoxonase
  71. activity. Acta Diabetol 2001;38:163-169. doi:
  72. s592-001-8074-z
  73. Gofman JW, Young W, Tandy R. Ischemic heart
  74. disease, atherosclerosis, and longevity. Circulation;34:679-697.
  75. Rozenberg O, Rosenblat M, Coelman R, et al.
  76. Paraoxonase (PON1) deficiency is associated with
  77. increased macrophage oxidative stres: studies in
  78. PON1-knockout mice. Free Radic Biol Med;34:774-784. doi: 10.1016/S0891-
  79. 01429-6
  80. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow
  81. GC, Carlinez CJ, Castellani LW. Mildly oxidised
  82. LDL induces an increased apolipoprotein
  83. J/paraoxonase ratio. J Clin Invest 1997;99:2005-
  84. doi: 10.1172/JCI119369
  85. Singh S, Venkatesh S, Verma JS, Verma M,
  86. Lellama CO, Goel RC. Paraoxonase(PON1) activity
  87. in North west Indian Punjabis with coronary artery
  88. disease. Indian J Med Res 2007;125:783-787.
  89. Jayakumari N, Thejaseebai G. High prevalence of
  90. low serum paraoxonase1 in subjects with coronary
  91. artery disease. J Clin Biochem Nutr 2009;45(3):278-
  92. doi: 10.3164/jcbn.08-255
  93. Kabaroğlu C, Mutaf I, Boydak B, et al. Association
  94. between serum paraoxonase activity and oxidative
  95. stress in acute coronary syndromes. Acta Cardiol;59:606-611.
  96. Aviram M, Rosenbalt M. Paraoxonases and
  97. cardiovascular diseases: pharmacological and
  98. nutritional influences. Curr Opin Lipidol;16:393-399.
  99. Suehiro T, Nakanchi Y, Yammamoto M, Arii K, Itoh
  100. H, Hamashige N, et al. Paraoxonase gene
  101. polymorphism in Japanese subjects with coronary
  102. heart disease. Br J Pharmacol 1996;57:69-73. doi:
  103. S0167-5273(96)02779-9
  104. Antikainen M, Mutomaki S, Syvanne M, Pahlman R,
  105. Tanvanainen E, Jauhianen M, et al. The Gln Arg
  106. polymorphism of human paraoxonase gene
  107. (HUMPONA) is not associated with the risk of
  108. coronary artery disease in Finns. J Clin Invest;98:883-885.
  109. Mukamal KJ, Pai JK, Jensen MK, Rimm EB.
  110. Paraoxonase 1 polymorphisms and risk of
  111. myocardial infarction in women and men. Circ J;73(7):1302-1307. doi: 10.1253/circj.CJ-08-
  112. Rios DL, D’Onofrio LO, Cerqueira CC, Bonfim-Silva
  113. R, Carvalho HG, Santos-Filho A, et al. Paraoxonase
  114. gene polymorphisms in angiographically
  115. assessed coronary artery disease: evidence for
  116. gender interaction among Brazilians. Clin Chem
  117. Lab Med 2007;45:874-878. doi:
  118. CCLM.2007.136
  119. Sanghera DK, Saha N, Aston CE, Kamboh MI.
  120. Genetic polymorphism of paraoxonase and the risk
  121. of coronary heart disease. Arterioscler Thromb
  122. Vasc Biol 1997;17:1067-1073.
  123. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C,
  124. CharpentierG, Cohen N, Morabia A, Passa P,
  125. Froguel P. Gln-Arg 192 polymorphism of
  126. Ö. TARÇIN
  127. Paraoksonaz-1 ve koroner kalp hastalığı
  128. Marmara Medical Journal 2011; 24 (1):59-63
  129. paraoxonase and coronary heart disease in type 2
  130. diabetes. Lancet 1995;346(8979):869-872.
  131. doi:10.1016/S0140-6736(95)92709-3
  132. Kaman D, İlhan N, Metin K, Akbulut M, Üstündağ B.
  133. A preliminary study of human paraoxonase and
  134. PON1 L/M55-PON1 Q/R192 polymorphisms in
  135. Turkish patients with coronary artery disease. Cell
  136. Biochem Funct 2009;27:88-92. doi:
  137. cbf.1539
  138. Özkök E, Aydın M, Babalık E, Özbek Z, İnce N,
  139. Kara İ. Combined impact of matrix
  140. metalloproteinase-3 and paraoxonase 1 55/192
  141. gene variants on coronary artery disease in Turkish
  142. Patients. Med Sci Monit 2008;14(19):536-542.
  143. Aynacıoğlu AS, Kepekçi Y. The human
  144. paraoxonase Gln-Arg 192(Q/R) polymorphism in
  145. Turkish patients with coronary artery disease. Int J
  146. Cardiol 2000;12:33-37. doi: 10.1016.S0167-
  147. 00242-4
  148. Wheeler JG, Keavney BD, Watkins H, Collins R,
  149. Danesh J. Four paraoxonase gene polymorphism in
  150. cases of coronary heart diseases and 12786
  151. controls: meta-analysis of 43 studies. Lancet;363(9410):689-695. doi: 10.1016/S0140-
  152. 15642-0
  153. Tartan Z, Orhan G, Kaşıkçıoğlu H, Uyarel H, Ünal
  154. S, Özer N, Özay B, Çiloğlu F, Çam N. The role of
  155. paraoxonase (PON) enzyme in the extent and
  156. severity of the coronary artery disease in type-2
  157. diabetic patients. Heart Vessels 2007;22(3):158-
  158. doi: 10.1007/s00380-0060957-6
  159. Ferretti G, Bacchetti T, Busni D, et al. Protective
  160. effect of paraoxonase activity in high-density
  161. lipoproteins against erythrocyte membranes
  162. peroxidation: a comparison between healthy
  163. subjects and type 1 diabetic patients. J Clin
  164. Endocrinol Metab 2004;89:2957-2962.
  165. Karabina SA, Lehner AN, Franke E, Parthasara S,
  166. Santanam N. Oxidative inactivation of paraoxonaseimplications
  167. in diabetes mellitus and
  168. atherosclerosis. Biochim Biophys Acta;1725(2):213-221. doi:
  169. j.bbagen.2005.07.005
  170. Flekac M, Skrha J, Zidkova K, Lacinova Z,
  171. Hilgertova J. Paraoxonase 1 gene polymorphisms
  172. and enzyme activities in diabetes mellitus. Physiol
  173. Res 2008;57(5):717-26.
  174. Chen X, Wu Y, Liu L, Su Y, Peng Y, Jiang L, Liu X,
  175. Huang D. Relationship between high density
  176. lipoprotein antioxidant activity and carotid intima
  177. media thickness in patients with essential
  178. hypertension. Clin Exp Hypertens 2010;32:13-20.
  179. Yıldız A, Gür M, Demirbağ R, Yılmaz R, Akyol S,
  180. Aslan M, Erel O. Paraoxonase and arylesterase
  181. activities in untreated dipper and non-dipper
  182. hypertensive patients. Clin Biochem 2008;41(10-:779-784. doi:
  183. j.clinbiochem.2008.02.010
  184. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N,
  185. Minami N, et al. Relation between nocturnal decline
  186. in blood pressure and mortality. The Ohasama
  187. Study. Am J Hypertens 1997;10:1201-1207. doi:
  188. S0895-7061(97)00274-4
  189. Metohi H, Ohkubo T, Kikuya M, Asayama K, Obara
  190. T, Hashimoto J, et al. Prognostic significance for
  191. stroke of a morning pressor surge and a nocturnal
  192. blood pressure decline:the Ohasama study.
  193. Hypertension 2006;47:149-154. doi:
  194. HYP.0000198541.12640.0f
  195. Connelly PW, Zinman B, Maguire GF,
  196. Mamakeesick M, Haris SB, Hegele RA, Retnakaren
  197. R, hanley AJ. Association of the novel
  198. cardiovascular risk factors paraoxonase 1 and
  199. cystatin C in type 2 diabetes. J Lipid res;50(6):1216-1222. doi: 10.1194/jlr.P80070-
  200. JLR200
  201. Ribas V, Sanchez-Quesada JL, Anton R, Camacho
  202. M, Julve J, Escola-Gil JC, Vila L, Ordonez-Llanos J,
  203. Blanco-Vaca F. Human apolipoprotein A-II
  204. enrichement displaces paraoxonase from HDL and
  205. impairs its antioxidant properties. Circ Res;95:789-797. doi:
  206. RES0000146031.94850.5f
  207. Paragh G, Seres I, Harangi M, Balogh Z, Illyes L, et
  208. al. The effect of micronised fenofibrate on
  209. paraoxonase activity in patients with coronary heart
  210. disease. Diabetes Metab 2003;29:613-618. doi:
  211. S1262-3636(07)70077-0
  212. Beltowski J, Wòjcicka G, Mydlarczyk M, Jamroz A.
  213. The effect of peroxisome proliferator-activated
  214. receptors (PPAR) alpha agonist, fenofibrate, on lipid
  215. peroxidation, total antioxidant capacity, and
  216. plasma paraoxonase 1(PON1) activity. J Physiol
  217. Pharmacol 2002;53:463-475.
  218. Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk Gy,
  219. Paragh Gy. Gemfibrozil increases paraoxonase
  220. activity in type 2 diabetic patients. A new hypothesis
  221. of the beneficial action of fibrates? Diabetes Metab;27:604-610.
  222. Durrington PN, Mackness MI, Bhatnagar D, Julier
  223. K, Prais H, Arrol S, Morgan J, Wood GNI. Effects of
  224. two different fibric acid derivatives on lipoproteins,
  225. cholesterol ester transfer, fibrinogen, plasminogen
  226. activator inhibitor and paraoxonase activity in type
  227. IIb hyperlipoproteinemia. Atherosclerosis;138:217-225. doi:
  228. ATV.0000027414.34728.1F
  229. Senti M, Tomas M, Anglada R, Elosua R, Marrugat
  230. J, Covas MI, et al. Inter-relationship of smoking,
  231. paraoxonase activity, and leisure time physical
  232. activity:a population based study. Eur J Int Med;14:178-184. doi: 10.10167S0953-
  233. 00041-4
  234. Mouhamed DH, Ezzaher A, Araoud M, Neffati F,
  235. Douki W, Najjar MF. Paraoxonase 1(PON1) activity
  236. and lipid parameters in Tunusian smokers. Ann Biol
  237. Clin 2010;68;143-147. doi: 10.1684/abc.2010.0418
  238. James RW, Leviev I, Righetti A. Smoking is
  239. associated with reduced serum paraoxonase
  240. activity and concentration in patients with coronary
  241. artery disease. Circulation 2000;101:2252-2257.
  242. Nishio E, Watanabe Y. Cigarette smoke extracts
  243. inhibits plasma paraoxonase activity by modification
  244. of the enzyme’s free thiols. Biochem Biophys Res
  245. Comm 1997;236:289-293. doi:
  246. bbrc.1997.6961